Federal Research Institute of Pediatric Hematology, Oncology and Immunology

🇷🇺Russia

Country: 🇷🇺Russia

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Emapalumab Efficacy in Children With Primary Hemophagocytic Lymphohistiocytosis

Active, not recruiting

Conditions: Primary Hemophagocytic Lymphohistiocytosis

First Posted Date: 2024-09-19

Last Posted Date: 2024-10-01

Lead Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Target Recruit Count: 7

Registration Number: NCT06587191

Locations: 🇷🇺
Research Institute of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation

Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia
Biphenotypic Acute Leukemia
Myelodysplastic Syndromes
Acute Lymphoblastic Leukemia
Malignant Lymphoma

Interventions: Drug: Baricitinib

First Posted Date: 2024-06-26

Last Posted Date: 2024-08-23

Lead Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Target Recruit Count: 150

Registration Number: NCT06475820

Locations: 🇷🇺
Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology and Immunology, Moscow, Samory-Mashela,1, Russian Federation

Abdominal Neuroblastoma Laparoscopic Surgery Risk Factors Stratification

Recruiting

Conditions: Ganglioneuroma
Neuroblastoma
Ganglioneuroblastoma

First Posted Date: 2024-03-06

Last Posted Date: 2024-05-20

Lead Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Target Recruit Count: 200

Registration Number: NCT06296732

Locations: 🇷🇺
Research Institute of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation

PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity

Phase 2

Recruiting

Conditions: Inborn Errors of Immunity

Interventions: Drug: Cyclophosphamide
Drug: Ruxolitinib

First Posted Date: 2024-01-10

Last Posted Date: 2024-01-10

Lead Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Target Recruit Count: 100

Registration Number: NCT06199427

Locations: 🇷🇺
HSCT department, Moscow, Russian Federation

Low Dose Treosulfan Based Conditioning Regimen and PTCy in HSCT for Nijmegen Breakage Syndrome

Phase 2

Recruiting

Conditions: Nijmegen Breakage Syndrome

Interventions: Drug: Treosulfan

First Posted Date: 2024-01-10

Last Posted Date: 2024-01-10

Lead Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Target Recruit Count: 10

Registration Number: NCT06198842

Locations: 🇷🇺
HSCT department, Moscow, Russian Federation

Induction Chemoimmunotherapy for Patients With High-risk Neuroblastoma

Phase 3

Recruiting

Conditions: Neuroblastoma
Ganglioneuroblastoma

Interventions: Drug: monoclonal antibodies GD2

First Posted Date: 2023-10-10

Last Posted Date: 2023-10-10

Lead Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Target Recruit Count: 15

Registration Number: NCT06071897

Locations: 🇷🇺
Research Institute of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation

Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies

Recruiting

Conditions: Primary Immunodeficiency Diseases (PID)

First Posted Date: 2023-08-14

Last Posted Date: 2023-08-14

Lead Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Target Recruit Count: 100

Registration Number: NCT05986734

Locations: 🇷🇺
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation

Efficacy and Safety of Sirolimus in Children and Adolescents With Juvenile Nasopharyngeal Angiofibroma (JNA)

Phase 3

Recruiting

Conditions: Juvenile Nasopharyngeal Angiofibroma

Interventions: Drug: Sirolimus

First Posted Date: 2022-09-22

Last Posted Date: 2022-09-22

Lead Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Target Recruit Count: 117

Registration Number: NCT05549167

Locations: 🇷🇺
Research Institute of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation

B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021

Phase 4

Recruiting

Conditions: Primary CNS Lymphoma
Diffuse Large B-cell Lymphoma
Primary Mediastinal Lymphoma
Non-hodgkin Lymphoma,B Cell
Burkitt Lymphoma

Interventions: Drug: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine
Drug: Cyclophosphamide , Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, Vincristine, Сarboplatine, CCNU/ BCNU, Melphalan, Idarubicin
Drug: Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine
Drug: Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate

First Posted Date: 2022-08-26

Last Posted Date: 2022-08-26

Lead Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Target Recruit Count: 300

Registration Number: NCT05518383

Locations: 🇷🇺
Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology and Immunology, Moscow, RF, Russian Federation

Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis

Phase 3

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia
Biphenotypic Acute Leukemia
Myelodysplastic Syndromes
Myeloblastic Leukemia
Malignant Lymphoma
Juvenile Myelomonocytic Leukemia

First Posted Date: 2022-08-25

Last Posted Date: 2023-09-28

Lead Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Target Recruit Count: 56

Registration Number: NCT05515029

Locations: 🇷🇺
Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology and Immunology, Moscow, Samory-Mashela,1, Russian Federation

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy